Aslam Fawad, Khan Nasim Ahmed
Division of Rheumatology, Mayo Clinic, Scottsdale, AZ, United States.
Division of Rheumatology, University of Arkansas for Medical Sciences & Central Arkansas Veterans Health Care System, Little Rock, AR, United States.
Front Med (Lausanne). 2018 Feb 16;5:39. doi: 10.3389/fmed.2018.00039. eCollection 2018.
Comorbidities influence the prognosis, clinical outcomes, disease activity, and treatment response in rheumatoid arthritis (RA). RA patients have a high-comorbidity burden necessitating their study. Comorbidity indices are used to measure comorbidities and to study their impacts on different outcomes. A large number of such indices are used in clinical research. Some indices have been specifically developed in RA patients.
This review aims to provide an overview of generic and specific comorbidity indices commonly used in RA research.
We performed a critical literature review of comorbidity indices in RA using the PubMed database.
RESULTS/DISCUSSION: This non-systematic literature review provides an overview of generic and specific comorbidity indices commonly used in RA studies. Some of the older but commonly used comorbidity indices like the Charlson comorbidity index and the Elixhauser comorbidity measure were primarily developed to estimate mortality risk from comorbid diseases. They were not specifically developed for RA patients but have been widely used in rheumatology comorbidity measurement. Of the many comorbidity indices available, only the rheumatic disease comorbidity index (RDCI) and the multimorbidity index have been specifically developed in RA patients. The functional comorbidity index was developed to look at functional disability and has been used in RA patients considering that morbidity is more important than mortality in such patients. While there is limited data comparing these indices, available evidence seems to favor the use of RDCI as it predicts mortality, hospitalization, disability, and healthcare utilization. The choice of the index, however, depends on several factors such as the population under study, outcome of interest, and sources of data. More research is needed to study the RA-specific comorbidity measures to make evidence-based recommendations for the choice of a comorbidity measure.
合并症会影响类风湿关节炎(RA)的预后、临床结局、疾病活动度及治疗反应。RA患者合并症负担较重,因此有必要对其进行研究。合并症指数用于衡量合并症,并研究其对不同结局的影响。临床研究中使用了大量此类指数。有些指数是专门针对RA患者开发的。
本综述旨在概述RA研究中常用的通用及特定合并症指数。
我们使用PubMed数据库对RA合并症指数进行了批判性文献综述。
结果/讨论:本非系统性文献综述概述了RA研究中常用的通用及特定合并症指数。一些较旧但常用的合并症指数,如查尔森合并症指数和埃利克斯豪泽合并症度量,最初主要是为了估计合并疾病的死亡风险而开发的。它们并非专门为RA患者开发,但已广泛用于风湿病合并症的测量。在众多可用的合并症指数中,只有风湿病合并症指数(RDCI)和多重合并症指数是专门针对RA患者开发的。功能合并症指数是为研究功能残疾而开发的,鉴于此类患者的发病率比死亡率更重要,该指数已在RA患者中使用。虽然比较这些指数的数据有限,但现有证据似乎支持使用RDCI,因为它可以预测死亡率、住院率、残疾率和医疗资源利用情况。然而,指数的选择取决于几个因素,如研究人群、感兴趣的结局和数据来源。需要更多研究来探讨RA特异性合并症测量方法,以便为合并症测量方法的选择提供循证建议。